Vildagliptin / Metformin hydrochloride Accord Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

vildagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, type 2 - legemidler som brukes i diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgjengelige data på forskjellige kombinasjoner).

Vildagliptin/Metformin Krka 50 mg / 1000 mg Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

vildagliptin/metformin krka 50 mg / 1000 mg

krka, d.d. novo mesto - vildagliptin / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 1000 mg

Vildagliptin/Metformin Krka 50 mg / 850 mg Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

vildagliptin/metformin krka 50 mg / 850 mg

krka, d.d. novo mesto - vildagliptin / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 850 mg

Vildagliptin/Metformin Sandoz 50 mg / 1000 mg Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

vildagliptin/metformin sandoz 50 mg / 1000 mg

sandoz - københavn - vildagliptin / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 1000 mg

Vildagliptin/Metformin Sandoz 50 mg / 850 mg Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

vildagliptin/metformin sandoz 50 mg / 850 mg

sandoz - københavn - vildagliptin / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 850 mg

Vildagliptin Krka 50 mg Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

vildagliptin krka 50 mg

krka, d.d. novo mesto - vildagliptin - tablett - 50 mg

Vildagliptin Accord 50 mg Նորվեգիա - Նորվեգերեն - Statens legemiddelverk

vildagliptin accord 50 mg

accord healthcare b.v. - vildagliptin - tablett - 50 mg

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

icandra (previously vildagliptin / metformin hydrochloride novartis)

novartis europharm limited - vildagliptin, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgjengelige data på forskjellige kombinasjoner).

Jalra Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

jalra

novartis europharm limited - vildagliptin - diabetes mellitus, type 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgjengelige data på forskjellige kombinasjoner).

Xiliarx Եվրոպական Միություն - Նորվեգերեն - EMA (European Medicines Agency)

xiliarx

novartis europharm limited - vildagliptin - diabetes mellitus, type 2 - legemidler som brukes i diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgjengelige data på forskjellige kombinasjoner).